METI Launches Roundtable for Development of Facilities for Demonstrations to Create New Products and Services that are “Friendly to Dementia Patients”
As an effort under the Project for Establishing a Public-Private Joint Demonstration Platform for Dementia Patients
August 7, 2018
The Ministry of Economy, Trade and Industry (METI) launched a roundtable of experts under the Project for Establishing a Public-Private Joint Demonstration Platform for Dementia Patients, a project commissioned to the Japan Agency for Medical Research and Development (AMED), and held the first meeting.
The round table aims to establish a new public-private joint platform on which the public and private sectors are able to create new products and services that are “friendly to dementia patients”--a goal set in Strategy for Investments for the Future 2018, approved by the Cabinet on June 15, 2018.
The Working Group of the Next-Generation Healthcare Industrial Council will release the reports on the progress in and materials related to the discussions by the roundtable.
Reference: Excerpts from Strategy for Investments for the Future 2018
―Change to Society 5.0 and Data-driven Society―
Chapter I. Basic perspectives and priority measures
3. Priority fields that Japan should tackle to realize the Society 5.0 policy and the pulling power of “flagship projects” toward change
(1) [ii] Projects for establishing a next-generation healthcare system
<Health, medical care and nursing care services optimized to individuals>
ii) Encouraging the public to maintain or improve their health by uniting efforts of the industrial, academia, government and private sectorsJapan should establish a public-private joint platform in FY2018 in order to develop demonstration fields in which municipalities, researchers, companies and other entities will collaborate in creating new products and services “friendly to dementia patients,” including development of an environment in which people are able to take preventive measures against dementia at very early stages of the symptoms, or receive support measures in living their daily lives and ensuring access to society even for those already suffering from dementia.
Establishing approaches to treating dementia patients through development of new medicines, an aim in dementia research, is considered to be very important. However, as seen in the announcement from Pfizer Inc., a U.S. pharmaceutical company, of its decision to stop research and development into new neuroscience drugs, including its work in Alzheimer’s-related diseases in January 2018, related industries have been raising awareness that development of new medicines for dementia is highly challenging.
Against this backdrop, Japan considers it necessary to develop an environment in which people are able to reduce the potential risk of dementia at the earliest stages of the symptoms, or for those already suffering from dementia, spend their lives in comfort even if they are suffering from a decline in cognitive function, in addition to the larger goals of preventing or curing dementia.
The roundtable aims to develop an environment in which people are able to reduce the potential risk of dementia in the earliest stages of the symptoms, and for those already suffering from dementia, receive measures that support them in daily life and ensure access to society and social connections. To this end, the roundtable will hold discussions focusing on points of contention involving current situations of related efforts, priority fields that Japan should focus on tackling and development of facilities for demonstrations under industry-academia-government collaboration.
[Conceptual flow of developing a public-private joint platform for addressing dementia]
Division in Charge
Healthcare Industries Division, Commerce and Service Industry Policy Group